This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: University of Florida Research Foundation Inc., University of Pennsylvania. Active years: 2021-2025.
Company Filing History:
2 out of 3,050 
2 out of 2,655 
Years Active: 2021-2025
Title: Michael T Massengill: Innovator in Retinal Treatment
Introduction
Michael T Massengill is a notable inventor based in Gainesville, FL (US). He has made significant contributions to the field of medical treatments, particularly in addressing genetic disorders such as retinitis pigmentosa. With a total of 2 patents, his work focuses on innovative methods to improve patient outcomes.
Latest Patents
Massengill's latest patents include "Compositions and methods for treatment of dominant retinitis pigmentosa." This patent outlines methods and compositions useful for treating retinitis pigmentosa by delivering interfering RNA to reduce the expression of mutant RHO alleles. Additionally, he holds a patent for "AAV vectors for treatment of dominant retinitis pigmentosa," which also involves delivering interfering nucleic acids to mitigate the effects of the disease.
Career Highlights
Throughout his career, Massengill has worked with esteemed institutions such as the University of Florida Research Foundation Inc and the University of Pennsylvania. His research has been pivotal in advancing the understanding and treatment of retinal diseases.
Collaborations
Some of his notable coworkers include Alfred Samuel Lewin and William Beltran. Their collaborative efforts have contributed to the development of innovative solutions in the field of retinal research.
Conclusion
Michael T Massengill's work exemplifies the impact of innovation in medical science, particularly in the treatment of genetic disorders. His patents and collaborations highlight his commitment to improving the lives of those affected by retinitis pigmentosa.